This week: FUJIFILM Irvine Scientific expands its Armstrong R&D Cell Culture Center of Excellence, Manchester BIOGEL’s hydrogel platform technology was recognized as ‘Most Impactful Emerging Technology’ at Lab Innovations 2021, Sartorius Stedim Biotech plans to launch new Cell Culture Technology Center in Ulm, Germany, Saint-Gobain Life Sciences and denovoMATRIX announce collaboration to bolster new product development.
The news highlights:
- FUJIFILM Irvine Scientific expands its Armstrong R&D Cell Culture Center of Excellence
- Manchester BIOGEL’s hydrogel platform technology recognized as ‘Most Impactful Emerging Technology’
- Sartorius Stedim Biotech plans to launch new Cell Culture Technology Center
- Saint-Gobain Life Sciences and denovoMATRIX announce collaboration
FUJIFILM Irvine Scientific expands its Armstrong R&D Cell Culture Center of Excellence
FUJIFILM Irvine Scientific (CA, USA) has announced its expansion of its Armstrong R&D Center of Excellence as its headquarters in California. Planned for completion by January 2022, the move is part of its commitment to the advancement of discovery research, bioproduction, cell and gene therapy, assisted reproductive technologies and cytogenetics in its Life Sciences and Medical Media divisions. The expanded footprint will enable additional cell culture and molecular-based assay development, dedicated space for analytical chemistry, virology, Assisted Reproductive Technology (ART), and growth of the R&D headcount.
“With society’s increasing demand for global access to more high-quality, cost-effective vaccines, biopharmaceuticals, cell-based therapies, gene therapies, and in–vitro fertilization procedures, the need for a broadened focus on innovation is pivotal to expedite critical product and technology development. The expansion project will more than double the R&D facility’s footprint and will allow for more enhanced technical collaboration between R&D experts and customers to develop personalized solutions and enhance partnership opportunities,” said Bob Newman, Chief Scientific officer, FUJIFILM Irvine Scientific.
Manchester BIOGEL’s hydrogel platform technology recognized as ‘Most Impactful Emerging Technology’
Manchester BIOGEL’s (Cheshire, UK) hydrogel platform technology has been recognized as the ‘Most Impactful Emerging technology’ at Lab Innovations 2021 at NEC Birmingham on November 2. Supported by UK-based science institutions, the aim of the event is to power the business of science, and to showcase the latest laboratory developments and equipment from leading scientific suppliers and manufacturers.
Senior Business Development Manager, Jessica Hutchinson, commented: “We are extremely honored to have received the ‘Most Impactful Emerging Technology’ award at Lab Innovations 2021. This reputable award recognizes our innovative peptide hydrogel technology, as well as the hard work the MBG team have put in over the past couple of years to continue to drive the company forward.”
Sartorius Stedim Biotech to launch new Cell Culture Technology Center
On November 18, 2021, Sartorius Stedim Biotech (Göttingen, Germany) will hold a virtual opening ceremony of their new Cell Culture Technology Center in Ulm, Germany. The center will include a laboratory and office space and aims to double Sartorius’ total space and workforce in the future. The hybrid facility will be dedicated to cell line development and cell culture media optimization and is located at Science Park III in Germany with an estimated investment of US$35.2M. Attendees can register for the virtual opening ceremony here: Sartorius (digivent.stream)
Saint-Gobain Life Sciences and denovoMATRIX announce collaboration
Saint-Gobain Life Sciences (OH, USA) and denovoMATRIX (Dresden, Germany) have entered a partnership focused on optimizing the performance of new products in development for cell culture and harvest for autologous therapies. The Master Service Agreement will bolster the synergy of consumable products from both companies and bring their combined R&D findings to the therapeutic market. The collaboration will begin immediately, utilizing both laboratory facilities in the United States and Germany.
Dejan Hušman, CEO of denovoMATRIX, commented “Integration of the latest technological innovations in the cell therapy space is essential to bring therapies to clinical trials and the mainstream as soon as possible. We are delighted to partner with Saint-Gobain Life Sciences to bring our technology platform to bear on the most critical challenges in autologous cell manufacturing.”
You might also like: